- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A307280
Wonbiogen (KOSDAQ:307280) Has Affirmed Its Dividend Of ₩20.00
The board of Wonbiogen Co., Ltd. (KOSDAQ:307280) has announced that it will pay a dividend on the 15th of April, with investors receiving ₩20.00 per share. This means that the annual payment will be 1.6% of the current stock price, which is in line with the average for the industry.
Wonbiogen's Future Dividend Projections Appear Well Covered By Earnings
We like a dividend to be consistent over the long term, so checking whether it is sustainable is important. Before making this announcement, Wonbiogen was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.
Over the next year, EPS could expand by 69.2% if recent trends continue. If the dividend continues on this path, the payout ratio could be 1.3% by next year, which we think can be pretty sustainable going forward.
View our latest analysis for Wonbiogen
Wonbiogen Doesn't Have A Long Payment History
Looking back, the dividend has been stable, but the company hasn't been paying a dividend for very long so we can't be confident that the dividend will remain stable through all economic environments. Since 2022, the annual payment back then was ₩50.00, compared to the most recent full-year payment of ₩100.00. This works out to be a compound annual growth rate (CAGR) of approximately 26% a year over that time. We're not overly excited about the relatively short history of dividend payments, however the dividend is growing at a nice rate and we might take a closer look.
The Dividend Looks Likely To Grow
Investors who have held shares in the company for the past few years will be happy with the dividend income they have received. We are encouraged to see that Wonbiogen has grown earnings per share at 69% per year over the past five years. A low payout ratio gives the company a lot of flexibility, and growing earnings also make it very easy for it to grow the dividend.
Wonbiogen Looks Like A Great Dividend Stock
Overall, we like to see the dividend staying consistent, and we think Wonbiogen might even raise payments in the future. Distributions are quite easily covered by earnings, which are also being converted to cash flows. All in all, this checks a lot of the boxes we look for when choosing an income stock.
Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. However, there are other things to consider for investors when analysing stock performance. For instance, we've picked out 1 warning sign for Wonbiogen that investors should take into consideration. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers.
Valuation is complex, but we're here to simplify it.
Discover if Wonbiogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A307280
Excellent balance sheet and good value.
Market Insights
Weekly Picks

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fiducian: Compliance Clouds or Value Opportunity?
Willamette Valley Vineyards (WVVI): Not-So-Great Value
Recently Updated Narratives
This one is all about the tax benefits
Estimated Share Price is $79.54 using the Buffett Value Calculation
Halyk Bank of Kazakhstan will see revenue grow 11% as their future PE reaches 3.2x soon
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
